Real-time enrollment status for this plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 1:21 PM UTC
| NCT Number | NCT04846959 |
| Recruiting Status | Recruiting |
| Condition | Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment |
| Phase | Clinical Trial |
| Target Enrollment | 818 participants |
| Active Locations | 2 sites in the US |
| Sponsor | AbbVie |
| Last Updated on CT.gov | July 17, 2025 (Jul 17, 2025) |
As of July 13, 2026: Clinical trial NCT04846959 is currently recruiting participants. This clinical trial study for plaque psoriasis, psoriatic arthritis, crohn's disease, or other conditions for which risankizumab is an fda-approved treatment is actively seeking new participants at 2 locations across the United States. The study is sponsored by AbbVie. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT04846959 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 2 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT04846959 was last updated Jul 17, 2025 (July 17, 2025). HelloStudys verifies this status automatically.